Nick Leslie

Prof. Dr. Nick Leslie

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2004 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
LHLaura S. Harrington
Laura S. Harrington
GFGreg M. Findlay
Greg M. Findlay
AGAlex Gray
Alex Gray
TTTatiana Tolkacheva
Tatiana Tolkacheva
SWSimon Wigfield
Simon Wigfield
RLRichard F. Lamb
Richard F. Lamb
Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K signals for its activation. Here, we show that TSC1-2 is required for insulin signaling to PI3K. TSC1-2 maintains insulin signaling to PI3K by restraining the activity of S6K, which when activated inactivates insulin receptor substrate (IRS) function, via repression of IRS-1 gene expression and via direct phosphorylation of IRS-1. Our results argue that the low malignant potential of tumors arising from TSC1-2 dysfunction may be explained by the failure of TSC mutant cells to activate PI3K and its downstream effectors.

15 October 2003 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
NLNick Leslie
Nick Leslie
DBDeborah Bennett
Deborah Bennett
YLYvonne E. Lindsay
Yvonne E. Lindsay
HSHazel Stewart
Hazel Stewart
AGAlex Gray
Alex Gray
CDC.PEter Downes
C.PEter Downes
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 August 2017 in Advances in Biological Regulation
Verified
Journal Article
Closed access
MHMiguel A. Hermida
Miguel A. Hermida
JKJ. Dinesh Kumar
J. Dinesh Kumar
NLNick Leslie
Nick Leslie

3 November 2008 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ASAna Silva
Ana Silva
JYJosé Andrés Yunes
José Andrés Yunes
BCBruno António Cardoso
Bruno António Cardoso
LMLeila R. Martins
Leila R. Martins
PJPatrícia Y. Jotta
Patrícia Y. Jotta
João T BarataJoão T Barata
João T Barata
Mutations in the phosphatase and tensin homolog (PTEN) gene leading to PTEN protein deletion and subsequent activation of the PI3K/Akt signaling pathway are common in cancer. Here we show that PTEN inactivation in human T cell acute lymphoblastic leukemia (T-ALL) cells is not always synonymous with PTEN gene lesions and diminished protein expression. Samples taken from patients with T-ALL at the time of diagnosis very frequently showed constitutive hyperactivation of the PI3K/Akt pathway. In contrast to immortalized cell lines, most primary T-ALL cells did not harbor PTEN gene alterations, displayed normal PTEN mRNA levels, and expressed higher PTEN protein levels than normal T cell precursors. However, PTEN overexpression was associated with decreased PTEN lipid phosphatase activity, resulting from casein kinase 2 (CK2) overexpression and hyperactivation. In addition, T-ALL cells had constitutively high levels of ROS, which can also downmodulate PTEN activity. Accordingly, both CK2 inhibitors and ROS scavengers restored PTEN activity and impaired PI3K/Akt signaling in T-ALL cells. Strikingly, inhibition of PI3K and/or CK2 promoted T-ALL cell death without affecting normal T cell precursors. Overall, our data indicate that T-ALL cells inactivate PTEN mostly in a nondeletional, posttranslational manner. Pharmacological manipulation of these mechanisms may open new avenues for T-ALL treatment.

1 December 2019 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
VÁVirginia Álvarez-Garcia
Virginia Álvarez-Garcia
YTYasmine Tawil
Yasmine Tawil
HWHelen M. Wise
Helen M. Wise
NLNick Leslie
Nick Leslie

1 April 2002 in Cellular Signalling
Verified
Journal Article
Closed access
NLNick Leslie
Nick Leslie
CDC.PEter Downes
C.PEter Downes